FDA Reissues Emergency Use Authorization For LumiraDx's COVID-19 Testing Solution

The FDA has reissued Emergency Use Authorization (EUA) to LumiraDx Ltd's LMDX SARS-CoV-2 RNA STAR Complete, a rapid nucleic acid amplification technology for high sensitivity, high throughput COVID-19 testing.

  • The EUA now includes testing of asymptomatic individuals, pooling of up to five individuals, access to 384-well configuration on validated open RT-PCR systems, and detection of Omicron variant.
  • LumiraDx SARS-CoV-2 RNA STAR Complete, developed with proprietary qSTAR technology, utilizes a single-step direct method for nucleic acid extraction and amplification on validated open RT-PCR instruments, with results within 20 minutes.
  • In October, LumiraDx received approval for its COVID-19 antigen test for use in India.
  • Price Action: LMDX shares are up 0.11% at $9.50 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsHealth CareFDAMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusDiagnostics
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!